Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 166

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 166
---
.
Under the amendment, or the Bukwang Amendment, Melior and Bukwang agreed that, upon us securing a minimum of $4.0 million in new equity
financing, the Bukwang License shall terminate in its entirety and Bukwang shall transfer to Melior all rights, titles and interests to
certain INDs, know-how and data, and patents relating to tolimidone.

| 84 |

Under the Bukwang Amendment,
Melior and Bukwang entered into the Proposed Royalty Agreement pursuant to which Bukwang shall be entitled to 50% of all payments Melior
receives under the Tolimidone License, including: (i) 50% of the equity issued by us under the Tolimidone License, and (ii) 50% of the
royalties that we will pay to Melior. Further, under the royalty agreement, Bukwang will pay to Melior $100,000 in consideration for Melior’s
waiver of Bukwang’s obligation to pay patent costs pursuant to the Bukwang License, and Melior will take back responsibility for
all tolimidone patent prosecution and maintenance costs.

CMS License Agreement.On January 29, 2019, we entered into the CMS License Agreement with CMS, as guarantor, and the Licensees. The CMS License Agreement
was effective as of February 26, 2019. Pursuant to the terms of the CMS License Agreement, we agreed to license to the Licensees the exclusive
right to use our technology and our intellectual property rights and information and data related to certain of our clinical and pre-clinical
products, including MTX110, together with any other pipeline products or line extensions which are in or which enter pre-clinical or clinical
development in the first three years following the effective time of the CMS License Agreement, together the Products, to develop and
commercialize the Products in China, including Macau, Hong Kong and Taiwan, with the same rights in certain countries in south east Asia
in respect of which the Licensees notifies us that such licensee wants a license after the grant of a regulatory approval of any of the
Products by the FDA, EMA or by the regulatory authorities in the United Kingdom, France, Germany or Switzerland, collectively the Territory,
such activities to be conducted by the Licensee(s) and affiliates of CMS and local partners as permitted sub-licensees. The Licensees
have the exclusive right to import, obtain market approvals and register, market, distribute, promote and